John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.